AzTrials
AzTrials

DrainageNCT07814573

Early Outcomes of Spontaneous vs. Negative-pressure Drainage After Coronary Artery Bypass Grafting

A study testing monitoring of drainage using negative pressure in people with Drainage and Complications Due to Coronary Artery Bypass Graft, run by Başakşehir Çam & Sakura City Hospital at 1 site in Turkey (Türkiye).

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The purpose of this prospective, randomized controlled clinical trial is to evaluate early postoperative outcomes and fluid drainage dynamics between continuous active negative-pressure chest drainage (-10 mmHg) and standard spontaneous closed underwater-seal drainage in adult patients undergoing elective isolated… Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
monitoring of drainage using negative pressure
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Sep 2026to 15 Sep 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients scheduled for elective, isolated coronary artery bypass grafting (CABG) via median sternotomy.
  • Adult patients aged from 18 to 80 years.
  • Patients who provide written informed consent prior to study enrollment.

Who cannot join

  • Patients undergoing emergency coronary artery bypass grafting (CABG) or emergency surgical re-exploration.
  • Patients under 18 years or over 80 years of age.
  • Patients undergoing re-do cardiac surgery.
  • Pre-existing pericardial effusion or significant pleural effusion detected on baseline imaging.
  • Pre-existing baseline coagulopathy or active bleeding disorder.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Başakşehir Çam Ve Sakura Şehir Hastanesi

    Istanbul, Istanbul, 34480

Other trials in Turkey (Türkiye)

About this study

Official title: Comparison of Early-stage Outcomes of Spontaneous Drainage Versus Negative-pressure Drainage Monitoring in Patients Undergoing Coronary Artery Bypass Grafting: a Prospective Randomized Controlled Study

The purpose of this prospective, randomized controlled clinical trial is to evaluate early postoperative outcomes and fluid drainage dynamics between continuous active negative-pressure chest drainage (-10 mmHg) and standard spontaneous closed underwater-seal drainage in adult patients undergoing elective isolated coronary artery bypass grafting (CABG).

Read the detailed description

Postoperative pericardial and pleural fluid accumulation following cardiac surgery can lead to complications such as postoperative atrial fibrillation (POAF), cardiac tamponade, or symptomatic pleural effusion. While low-intensity negative-pressure suction is commonly used in general thoracic procedures, its routine application in cardiac surgery remains debated.This prospective randomized study evaluates whether maintaining continuous low-intensity active negative-pressure chest drainage (-10mmHg) during the first 48 hours postoperatively improves early fluid evacuation and reduces early morbidity compared with conventional spontaneous closed underwater-seal chest drainage.

Being tested
monitoring of drainage using negative pressure
Keywords
drainage, cabg, coronary artery bypass graft, cardiovascular surgery, cardiac surgery

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • monitoring of drainage using negative pressureProcedure or surgery

    Continuous low-intensity active negative-pressure suction (-10mmHg) applied to chest drains via central vacuum wall suction for the first 48 hours postoperatively following coronary artery bypass grafting (CABG).

Study groups in NCT07814573
Study groupRoleWhat they receive
No-Negative Pressure GroupNo interventionpatients not subjected to negative pressure and managed with routine underwater-seal drainage
Negative Pressure GroupActive comparatorpatients monitored under negative pressure
Receives: Procedure: monitoring of drainage using negative pressure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pre-discharge echocardiographic assessment

    Pericardial effusion volume and left ventricular ejection fraction (LVEF) measured in percentage (%) via transthoracic echocardiography prior to hospital discharge.

    Measured: 7-14 days after the surgery

  2. Cumulative drainage volume at 24 and 48 hours

    Total volume of thoracic drainage fluid measured in milliliters (mL) at 24 and 48 hours postoperatively.

    Measured: First 24 and 48 hours after the surgery

  3. Incidence of postoperative complications

    Rate of early complications occurring within 48 hours postoperatively, including postoperative atrial fibrillation (POAF), pneumothorax, and symptomatic pleural effusion requiring intervention.

    Composite rate of major complications within 30 days postoperatively, including surgical re-exploration for bleeding or cardiac tamponade, requirement for extracorporeal membrane oxygenation (ECMO) support, deep sternal wound infection or sternal revision, and 30-day all-cause mortality.

    Measured: It will be evaluated during the patient follow-ups at the first 48 hours and the one-month check-ups.

Secondary outcomes (2)
  1. Postoperative recovery metrics

    Intensive care unit (ICU) length of stay and total hospital length of stay measured in days

    Measured: from surgery to discharge (5-30 days)

  2. Duration of intubation

    the time elapsed from the point of intubation at the start of the operation until extubation

    Measured: 10-360 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Sep 2026
  2. Study start1 Sep 2026
  3. Primary completion31 Aug 2027 (estimated)
  4. Study completion15 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07814573
Sponsor's protocol ID
123
Status last verified
Sep 2026
First submitted
5 Sep 2026
Last updated
22 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Patient data cannot be shared with third parties, as specified during the ethics committee application.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in